AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18573718 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mM TauBr cream
Number of subjects: 40
Study 18573718 — intervention group
Group type: COMPARATOR
Intervention: 1% Clindamycin gel (Clindacin T)
Number of subjects: 40
Study 17312341 — intervention group
Group type: EXPERIMENTAL
Intervention: Older UVH
Number of subjects: 31
Study 17312341 — intervention group
Group type: EXPERIMENTAL
Intervention: Older CON
Number of subjects: 31
Study 17312341 — intervention group
Group type: EXPERIMENTAL
Intervention: Older UVH and Older CON
Number of subjects: 31
Study 17312341 — intervention group
Group type: COMPARATOR
Intervention: Young CON
Number of subjects: 31
Study 14716362 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 0
Study 10731011 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.3 g x kg(‐1))
Number of subjects: 8
Study 10731011 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl (0.21 g x kg(‐1))
Number of subjects: 8
Study 10731011 — intervention group
Group type: COMPARATOR
Intervention: Placebo Control (PC)
Number of subjects: 8
Study 10731011 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3
Number of subjects: 8
Study 10731011 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl
Number of subjects: 8
Study 10731011 — intervention group
Group type: COMPARATOR
Intervention: PC
Number of subjects: 8
Study 9193187 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portasystemic shunt (TIPS)
Number of subjects: 40
Study 9193187 — intervention group
Group type: COMPARATOR
Intervention: Small-diameter prosthetic H-graft portacaval shunt (HGPCS)
Number of subjects: 40
Study 1382132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study 1382132 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 0
Study 1382132 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0
Study 1382132 — intervention group
Group type: EXPERIMENTAL
Intervention: All three antihistamines (Cetirizine, Promethazine, Chlorpheniramine)
Number of subjects: 0
Study 3515919 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (50 mg orally twice a day)
Number of subjects: 143
Study 3515919 — intervention group
Group type: COMPARATOR
Intervention: Sulindac (150 mg orally twice a day)
Number of subjects: 143
Study 29915914 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aspirin use
Number of subjects: 403
Study 29915914 — intervention group
Group type: COMPARATOR
Intervention: Control (non-users of aspirin)
Number of subjects: 403
Study 26663880 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg, then 150 mg d(-1)) plus Aspirin (100 mg d(-1))
Number of subjects: 44
Study 26663880 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus Placebo
Number of subjects: 44
Study 26663880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg) plus Aspirin (300 mg)
Number of subjects: 44
Study 26663880 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor plus Placebo
Number of subjects: 44
Study 26663880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus Aspirin
Number of subjects: 44
Study 26663880 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus Aspirin
Number of subjects: 44
Study 23989971 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol+Laser
Number of subjects: 517
Study 23989971 — intervention group
Group type: COMPARATOR
Intervention: Polidocanol
Number of subjects: 517
Study 22542489 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (ETr; n=20)
Number of subjects: 60
Study 22542489 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination training (CTr; n=20)
Number of subjects: 60
Study 22542489 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mobility training (n=20)
Number of subjects: 60
Study 22542489 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 20706107 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus DNA testing
Number of subjects: 956
Study 20706107 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid
Number of subjects: 956
Study 20706107 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 956
Study 18971491 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive phototherapy
Number of subjects: 1974
Study 18971491 — intervention group
Group type: COMPARATOR
Intervention: Conservative phototherapy
Number of subjects: 1974
Study 15942159 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran supplement (2 oat bran-enriched muffins per day, 28 g/day of oat bran)
Number of subjects: 34
Study 15942159 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 34
Study 15942159 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran supplement
Number of subjects: 34
Study 11936532 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized iloprost (15 microg)
Number of subjects: 10
Study 10464004 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl‐trinitrate (24 h/day)
Number of subjects: 36
Study 10464004 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl‐trinitrate (16 h/day)
Number of subjects: 36
Study 10464004 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 36
Study 7628025 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg.kg‐1
Number of subjects: 75
Study 7628025 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal thiopentone 35 mg.kg‐1
Number of subjects: 75
Study 7628025 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 75
Study 2127268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil, 5-day treatment
Number of subjects: 0
Study 2127268 — intervention group
Group type: COMPARATOR
Intervention: Penicillin, 10-day treatment
Number of subjects: 0
Study 7208257 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus intensity at 40, 55, and 70 dB SPL with varying SOA (0, 1, 2, and 4 to 28 msec in 4-msec steps)
Number of subjects: 20
Study 7208257 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus intensity and SOA
Number of subjects: 20
Study 7208257 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus intensity
Number of subjects: 20
Study 7208257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity by SOA by Task interaction
Number of subjects: 20
Study 7208257 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal order task
Number of subjects: 20
Study 31046014 — intervention group
Group type: EXPERIMENTAL
Intervention: Online eye drop technique educational video
Number of subjects: 43
Study 28132059 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun anastomosis
Number of subjects: 68
Study 28132059 — intervention group
Group type: COMPARATOR
Intervention: Non-Braun anastomosis
Number of subjects: 68
Study 28132059 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 28132059 — intervention group
Group type: EXPERIMENTAL
Intervention: DGE presence
Number of subjects: 68
Study 26275480 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 vaccine
Number of subjects: 0
Study 26275480 — intervention group
Group type: COMPARATOR
Intervention: PPV23 vaccine
Number of subjects: 0
Study 26275480 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive treatment
Number of subjects: 0
Study 26275480 — intervention group
Group type: COMPARATOR
Intervention: TNF‐α treatment
Number of subjects: 0
Study 23600452 — intervention group
Group type: EXPERIMENTAL
Intervention: VBN-assisted ultrathin bronchoscopy
Number of subjects: 350
Study 23600452 — intervention group
Group type: COMPARATOR
Intervention: Non-VBN-assisted group
Number of subjects: 350
Study 23600452 — intervention group
Group type: EXPERIMENTAL
Intervention: VBN-assisted ultrathin bronchoscopy for right upper lobe lesions
Number of subjects: 350
Study 23600452 — intervention group
Group type: COMPARATOR
Intervention: Non-VBN-assisted group for right upper lobe lesions
Number of subjects: 350
Study 23600452 — intervention group
Group type: EXPERIMENTAL
Intervention: VBN-assisted ultrathin bronchoscopy for lesions invisible on posterior-anterior radiographs
Number of subjects: 350
Study 23600452 — intervention group
Group type: COMPARATOR
Intervention: Non-VBN-assisted group for lesions invisible on posterior-anterior radiographs
Number of subjects: 350
Study 23600452 — intervention group
Group type: EXPERIMENTAL
Intervention: VBN-assisted ultrathin bronchoscopy for lesions in the peripheral third of the lung field
Number of subjects: 350
Study 23600452 — intervention group
Group type: COMPARATOR
Intervention: Non-VBN-assisted group for lesions in the peripheral third of the lung field
Number of subjects: 350
Study 21844413 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for acute rhinosinusitis
Number of subjects: 166
Study 19828373 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQoL assessment using EORTC QLQ-C30
Number of subjects: 935
Study 19828373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue assessment using Multidimensional Fatigue Inventory (MFI-20)
Number of subjects: 935
Study 19828373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue at the end of treatment as a predictive variable for persistent fatigue
Number of subjects: 935
Study 16768837 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS) 25-30 g/d
Number of subjects: 11
Study 16768837 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (control)
Number of subjects: 11
Study 15606633 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon plus ribavirin
Number of subjects: 21
Study 15606633 — intervention group
Group type: COMPARATOR
Intervention: Standard interferon plus ribavirin
Number of subjects: 21
Study 11642626 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccines (HbOC or Hib-OMP)
Number of subjects: 0
Study 11642626 — intervention group
Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine (PnPs)
Number of subjects: 0
Study 9539303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) at a dose of 0.5-1.5 mg/week (n = 7)
Number of subjects: 17
Study 9539303 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (BRC) at a dose of 5-15 mg/day (n = 10)
Number of subjects: 17
Study 7859174 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam hydrochloride (50 micrograms/kg)
Number of subjects: 393
Study 7859174 — intervention group
Group type: COMPARATOR
Intervention: Droperidol (50 micrograms/kg)
Number of subjects: 393
Study 2816802 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg zinc (gluconate)
Number of subjects: 0
Study 2816802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1234492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 12
Study 30665869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg IV every 2 weeks)
Number of subjects: 292
Study 30665869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 28923219 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management of gastrointestinal stromal tumors
Number of subjects: 0
Study 28923219 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management of gastrointestinal stromal tumors
Number of subjects: 0
Study 28923219 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance based on studies
Number of subjects: 0
Study 26329410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cover wound dressing (n = 20)
Number of subjects: 40
Study 26329410 — intervention group
Group type: COMPARATOR
Intervention: No cover dressing (n = 20)
Number of subjects: 40
Study 23851398 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 60
Study 23851398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22159849 — intervention group
Group type: EXPERIMENTAL
Intervention: ORIF with a volar locking plate (n = 36)
Number of subjects: 73
Study 22159849 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and plaster immobilization (n = 37)
Number of subjects: 73
Study 19015347 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg of body weight weekly (arm A)
Number of subjects: 22
Study 19015347 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg loading dose followed by 6 mg/kg every 2 weeks (arm B)
Number of subjects: 22
Study 19015347 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg every 2 weeks for five doses (arm C)
Number of subjects: 22
Study 19015347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibalizumab (all arms)
Number of subjects: 22
Study 16785153 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (GnRH‐ant)
Number of subjects: 60
Study 14963375 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback-based balance training (exercise group, n = 20)
Number of subjects: 27
Study 14963375 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 27
Study 11404520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX)
Number of subjects: 244
Study 11404520 — intervention group
Group type: COMPARATOR
Intervention: Dapsone-pyrimethamine (DP)
Number of subjects: 244
Study 9423751 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride 200 mg/day
Number of subjects: 100
Study 9423751 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride 600 mg/day
Number of subjects: 100
Study 9423751 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (Premarin 0.625 mg/day)
Number of subjects: 100
Study 9423751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8423538 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.1‐0.32 mg/70 kg)
Number of subjects: 4
Study 8423538 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐Amphetamine (5 and 20 mg/70 kg)
Number of subjects: 4
Study 8423538 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel-response procedure
Number of subjects: 4
Study 8423538 — intervention group
Group type: COMPARATOR
Intervention: Two-response procedure
Number of subjects: 4
Study 3310771 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (angiotensin-converting enzyme inhibitor)
Number of subjects: 10
Study 3310771 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study 30519807 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 700
Study 30519807 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI
Number of subjects: 700
Study 28368869 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) therapy administered in 12 one-hour sessions over a 1-month period.
Number of subjects: 60
Study 28368869 — intervention group
Group type: COMPARATOR
Intervention: Control group measured on the Subjective Units of Distress Scale and a pain-rating scale at initial session, 1-month, and 24-month follow-up.
Number of subjects: 60
Study 25344589 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salicylate diet (LS)
Number of subjects: 10
Study 23821089 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based group-mediated cognitive behavioral walking intervention
Number of subjects: 194
Study 23821089 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 194
Study 21858735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (15 mg/day)
Number of subjects: 19
Study 21858735 — intervention group
Group type: COMPARATOR
Intervention: Control (no nicorandil)
Number of subjects: 19
Study 18295282 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal mucosa grafts
Number of subjects: 30
Study 18295282 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular bladder matrix grafts
Number of subjects: 30
Study 18295282 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Buccal mucosa and Acellular bladder matrix)
Number of subjects: 30
Study 16802767 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg daily)
Number of subjects: 360
Study 16802767 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone (200 microg twice daily)
Number of subjects: 360
Study 16802767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 16802767 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Number of subjects: 360
Study 16802767 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 360
Study 14503438 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory training for 4 weeks followed by motor training for 4 weeks
Number of subjects: 21
Study 14503438 — intervention group
Group type: COMPARATOR
Intervention: Motor training for 4 weeks followed by sensory training for 4 weeks
Number of subjects: 21
Study 10817717 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dOTC (800 mg)
Number of subjects: 12
Study 10817717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dOTC (100 mg)
Number of subjects: 12
Study 10817717 — intervention group
Group type: EXPERIMENTAL
Intervention: (+) dOTC
Number of subjects: 12
Study 8751401 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (RT) consisting of intracavitary brachytherapy alone to a median dose of 21 Gy for 17 patients.
Number of subjects: 98
Study 8751401 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (RT) consisting of external beam RT to a median dose of 45 Gy followed by intracavitary brachytherapy to a median dose of 12 Gy for 81 patients.
Number of subjects: 98
Study 8751401 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (RT)
Number of subjects: 98
Study 2059396 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine gastrointestinal therapeutic system (GITS)
Number of subjects: 394
Study 2059396 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 394
Study 6137427 — intervention group
Group type: EXPERIMENTAL
Intervention: Solpadeine (paracetamol 500 mg, codeine phosphate 8 mg, caffeine 30 mg)
Number of subjects: 0
Study 6137427 — intervention group
Group type: COMPARATOR
Intervention: Soluble DNP (dextropropoxyphene napsylate equivalent to 32.5 mg hydrochloride and paracetamol 325 mg)
Number of subjects: 0
Study 31542525 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analysis of myocardial perfusion
Number of subjects: 77
Study 31542525 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiquantitative analysis of myocardial perfusion
Number of subjects: 77
Study 31542525 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully quantitative analysis of myocardial perfusion
Number of subjects: 77
Study 31542525 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress myocardial blood flow analysis
Number of subjects: 77
Study 31542525 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial flow reserve (MFR) analysis
Number of subjects: 77
Study 30858609 — intervention group
Group type: EXPERIMENTAL
Intervention: 4400 IU vitamin D daily
Number of subjects: 0
Study 30858609 — intervention group
Group type: COMPARATOR
Intervention: 400 IU vitamin D daily (Control)
Number of subjects: 0
Study 29774628 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole 2 mg
Number of subjects: 459
Study 29774628 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole 4 mg
Number of subjects: 459
Study 29774628 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole 1 mg
Number of subjects: 459
Study 29774628 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 459
Study 26836351 — intervention group
Group type: EXPERIMENTAL
Intervention: Handtevy LBT™
Number of subjects: 80
Study 26836351 — intervention group
Group type: COMPARATOR
Intervention: Broselow Pediatric Emergency Tape™
Number of subjects: 80
Study 24457632 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-drug therapy (N = 14)
Number of subjects: 40
Study 24457632 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-drug therapy (N = 26)
Number of subjects: 40
Study 22992714 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (for men)
Number of subjects: 1789
Study 22992714 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (for women)
Number of subjects: 1789
Study 22992714 — intervention group
Group type: EXPERIMENTAL
Intervention: Being married (for men)
Number of subjects: 1789
Study 22992714 — intervention group
Group type: EXPERIMENTAL
Intervention: Being married (for women)
Number of subjects: 1789
Study 20595280 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-management program with telephone support
Number of subjects: 46
Study 20595280 — intervention group
Group type: COMPARATOR
Intervention: Control group (weekly attention-control phone calls)
Number of subjects: 46
Study 18056185 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete remission (CR) in patients with multiple myeloma
Number of subjects: 326
Study 11491010 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole 400 mg with ivermectin 200 micrograms/kg
Number of subjects: 47
Study 11491010 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole 400 mg with diethylcarbamazine citrate (DEC) 6 mg/kg
Number of subjects: 47
Study 11491010 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole 600 mg with ivermectin 400 micrograms/kg
Number of subjects: 47
Study 9122358 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral naltrexone
Number of subjects: 29
Study 9122358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 8319375 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month)
Number of subjects: 18
Study 8319375 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Number of subjects: 18
Study 8319375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3520133 — intervention group
Group type: COMPARATOR
Intervention: 20 mg BAYo1248 administered prior to breakfast
Number of subjects: 0
Study 3520133 — intervention group
Group type: COMPARATOR
Intervention: 50 mg BAYm1099 administered prior to breakfast, lunch, and dinner
Number of subjects: 0
Study 3520133 — intervention group
Group type: COMPARATOR
Intervention: BAYo1248 and BAYm1099
Number of subjects: 0